Sisunatovir
Sponsors
Pfizer Inc., Pfizer
Conditions
HealthyRespiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus InfectionRespiratory Syncytial Viruses
Phase 1
A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
CompletedNCT05712460
Start: 2023-02-08End: 2023-04-28Updated: 2024-09-19
A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.
CompletedNCT05878522
Start: 2023-05-15End: 2023-10-30Updated: 2024-12-06
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
CompletedNCT05987072
Start: 2023-11-03End: 2023-12-31Updated: 2025-02-24
A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.
CompletedNCT05994963
Start: 2023-09-01End: 2024-02-26Updated: 2025-05-06
A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.
CompletedNCT06105983
Start: 2023-11-03End: 2024-07-19Updated: 2025-04-24
C5241009 - An interventional, Phase 1b, randomized, double-blind, sponsor-open, placebo-controlled, multi-center, dose-finding study to evaluate safety, tolerability and pharmacokinetics of sisunatovir in pediatric participants up to age 60 months with Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI)
WithdrawnCTIS2023-504425-39-00
Target: 16Updated: 2023-11-06